ArticleExpert opinion on biological therapy2024
Stem cell therapy for type-2 diabetes: keeping the pedal to the metal to deliver translation to the clinic.
Ning Yang, LaTonya J Hickson, Lilach O Lerman
Abstract readEditorial
In one paragraphArticle in Expert opinion on biological therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Ning YangDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
LaTonya J HicksonDivision of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.
Lilach O LermanDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Funding
Obesity-induced dysfunction of human MSC in peripheral microvascular repairR01HL158691 · NHLBI · MAYO CLINIC ROCHESTER · PI Alfonso Eirin, Lilach O Lerman · 2022 to 2026
$3.4MObesity-induced mesenchymal stem cell senescenceR01DK120292 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2019 to 2022
$2.6MExtracellular vesicle-based senotherapeutics for aging diabetic kidneydiseaseR01AG076537 · NIA · MAYO CLINIC JACKSONVILLE · PI LaTonya J Hickson · 2023 to 2026
$2.3MQuantitative magnetization transfer MRI for evaluation of renal fibrosisR01DK122734 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2023
$2.2MMesenchymal stem cell senescence in diabetic nephropathy (K23 COVID Admin Supplement)K23DK109134 · NIDDK · MAYO CLINIC ROCHESTER · PI HICKSON, LATONYA J · 2016 to 2021
$1.0MRenal repair effects of senolytic preconditioned mesenchymal stromal PP #o20-111cells in diabetic kidney diseaseR03DK123492 · NIDDK · MAYO CLINIC ROCHESTER · PI HICKSON, LATONYA J · 2020 to 2021
$467kNoninvasive Evaluation of Renal Allograft Fibrosis by MRIR21AG062104 · NIA · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2021
$414kNHLBI NIH HHS R01 HL158691NIA NIH HHS R01 AG076537NIA NIH HHS R21 AG062104NIDDK NIH HHS K23 DK109134NIDDK NIH HHS R01 DK120292NIDDK NIH HHS R01 DK122734NIDDK NIH HHS R03 DK123492
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
efficacymechanismsmesenchymal stem cellssafetyT2DM
Identifiers
PMID39450809
PMCPMC11606765
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390